Bristol Myers Squibb (CELG-RI) Interest Expenses (2012 - 2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Interest Expenses of $50.0 million for Q1 2013, up 19.05% YoY from $42.0 million in Q1 2012, and up 19.05% sequentially from $42.0 million in Q1 2012.
Bristol Myers Squibb (CELG-RI) Interest Expenses (2012 - 2013) Analysis & Trends
Bristol Myers Squibb has disclosed Interest Expenses across 2 years of filings, most recently posting $50.0 million for Q1 2013.
- In Q1 2013, Interest Expenses rose 19.05% year-over-year to $50.0 million; the TTM figure through Dec 2013 stood at $50.0 million (up 19.05% YoY), while the FY2012 annual figure was $182.0 million, up 25.52% from the prior year.
- Interest Expenses rose to $50.0 million in Q1 2013, from $42.0 million in the prior quarter.
- Over the last five years, Interest Expenses for CELG-RI reached as high as $50.0 million in Q1 2013 and fell as low as $42.0 million in Q1 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 272.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -393.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 657.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 240.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | -343.00 Mn |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 50.00 Mn |
| Mar 31, 2013 | 50.00 Mn |
| Mar 31, 2012 | 42.00 Mn |
| Mar 31, 2012 | 42.00 Mn |